Biosynthesis inhibitors for leukotrienes in bronchial asthma

Allergologia et Immunopathologia

Volumn 25, Issue 4, 1997, Pages 209-216

  Negro, J M ^a,d   Miralles, J C ^b   Ortiz, J L ^c   Funes, E ^a   Garcia A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b Nuestra Sra del Rosel Hospital   (Spain)

^c Allergic Unit   (Spain)

^d Residencial La Paloma 'A 1 ^*  (Spain)

Author keywords

5 Lipoxygenase Protein Inhibitors; 5 Lipoxygenase Activating Protein Inhibitors; A 64077; A 78773; AA 681; ABT 761; BAYX 1005; BI 6239; FR 110302; L 699333; L 746530; MK 0591; MK 886; U 60257; ZD 2138; ZM 230487

Indexed keywords

2 (4 (QUINOLIN 2 YL METHOXY)PHENYL) 2 CYCLOPENTYLACETIC ACID; 2,2 DIBUTYL 1,2,3,4 TETRAHYDRO 5 (2 QUINOLYLMETHOXY) 1 NAPHTHOL; 2-(4-(QUINOLIN-2-YL-METHOXY)PHENYL)-2-CYCLOPENTYLACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; ANTIASTHMATIC AGENT; BENZOQUINONE DERIVATIVE; DOCEBENONE; DRUG DERIVATIVE; HYDROXYUREA; INDOLE DERIVATIVE; LEUKOTRIENE; LIPOXYGENASE INHIBITOR; NAPHTHOL DERIVATIVE; PIRIPROST; PROSTACYCLIN; PYRAN DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; ZILEUTON;

ASTHMA; BIOSYNTHESIS; CHEMICAL PHENOMENA; HUMAN; REVIEW;

ANTI-ASTHMATIC AGENTS; ASTHMA; BENZOQUINONES; DEPRESSION, CHEMICAL; EPOPROSTENOL; HUMANS; HYDROXYUREA; INDOLES; LEUKOTRIENES; LIPOXYGENASE INHIBITORS; NAPHTHOLS; PYRANS; QUINOLINES; QUINOLONES;

EID: 0031179948     PISSN: 03010546     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysolethicin like substances by cobra venom. J Physiol 1938;94:187-226
2. Kellaway CH, Threthewie RE. The liberation of a slow reacting smooth muscle stimulating substance of anaphylaxis J Exp Physiol 1940,30.121-45
3. Samuelsson B Leukotrienes mediators of immediate hypersensitivity reactions and inflammation Science 1983;220 (4597):568-75
4. Borgeat P, Samuelsson B. Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes Formation of a novel dihydroxy eicosanoic acid J Biol Chem 1979,254:2643-6.
5. Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: a slow reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA 1979;76.4275-9
6. Holtzman MJ. Arachidonic acid metabolism. Am Rev Respir Dis 1991,143:1 188-203.
7. Drazen JM, Austen KF. Leukotrienes and airway responses Am Rev Respir Dis 1987;136:4:985-98
8. 4. J Biol Chem 1989,264.33:19469-72.
9. 4 hydrolase Complete primary structure of an enzyme involved in eicosanoid synthesis J Biol Chem 1987, 262:29:13873-6.
10. Henderson WR Jr. Eicosanoids and platelet-activating factor in allergic respiratory diseases Am Rev Respir Dis 1991;143 5 Pt 2:S86-90
11. 4 synthetase Proc Natl Acad Sci USA 1992;89:23:11603-6
12. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987;237:4819:1171-6
13. 4 or its omega-metabolites Biochemistry 1987;241:1:55-62.
14. Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene. Nature 1990;343:6255 282-4
15. Miller DK, Gillard JW, Vickers PJ, Sadowski S, Leveille C, Mancini JA et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990;343. 6255.278-81.
16. Crocker IC, Townley RG. Leukotrienes: they receptors, antagonists and synthesis inhibitors In: Townley RG, Agrawal DK, eds. Immunopharmacology of allergic disease. New York: Marcel Dekker, 1996 p.433-61.
17. Jonsson EWE, Dahlen SE Interactions between leukotrienes and histamine in the anaphylactic contraction of guinea pig lung parenchyma. J Pharmacol Exp Ther 1994,271:2:615-23.
18. Bjorck T, Dahlen SE Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and nonasthmatic subjects Pulm Pharinacol 1993;6:1:87-96.
19. Diamant Z, Timmers MC, van der Veen H, Friedman BS, De Smet M, Depre M et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995,95:1Pt 1: 42-51.
20. Obata T, Yamashita N, Nakagawa T Leukotriene and thromboxane antagonists. Clin Rew Allergy 1994;12:1:79-93.
21. Ford Hutchison AW. Leukotriene antagonists and inhibitors as modulators of IgE-mediated reactions. Springle Semin Immunopathol 1993;15:37-50.
22. Ishida K, Thomson RJ, Schellenberg RR Role of leukotrienes in airway hyperresponsiveness in guinea pigs. Br J Phannacol 1993;108:3:700-4
23. Friedman BS, Bel EH, Buntinx A, Tanaka W, Han YH, Shingo S et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993;147.4 839-44
24. Holgate ST, Phillips GD. Inhibidores y antagonista de los leucotrienos en el asma In. Kay AB, Ed Alergia y asma Nuevas tendencias y orientaciones terapeúticas Barcelona: Mayo, 1991 p.28-51.
25. Ancill RJ, Takahashi Y, Kibune Y, Campbell R, Smith JR. Randomized double-blind, placebo-controlled clinical trial of a selective 5-lipoxygenase inhibitor (AA-861) for the prevention of seasonal allergic rhinitis J Int Med Res 1990;18:75-88.
26. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL et al 5-Lipoxygenase inhibitory activity of zileuton. J Phannacol Exp Ther 1991;256.3.929-37
27. Knapp HR Reduced allergen-induced nasal symptoms and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor [See comments]. N Engl J Med 1990;323.1745-8.
28. Israel E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P et al The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air [See comments] N Engl J Med 1990;323.1740-4.
29. Israel E, Fischer AR, Rosenberg MA, Lilly CM, Gallery JC, Shapiro J et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin Am Rev Respir Dis 1993;148:6Pt 1.1447-51.
30. Hui KP, Taylor IK, Taylor GW, Rubin P, Kesterton J, Barnes NC et al Effects of a 5-lypoxigenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991,46.184-9.
31. Collawn C, Rubin P, Perez N, Bobadilla J, Cabrera G. Reyes E Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis Am J Gastroenterol 1992;87:342-6.
32. 4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis Rheum 1990;33:1149-55
33. Drazen JM, Israel E. Treatment of chronic stable asthma with drugs active on the 5-lipoxygenase patway Int Arch Allergy Immunol 1995;107:3.319-20
34. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercice-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor Am J Respir Crit Care Med 1996;153 931-5
35. Swanson U, Doan TT, Dube LM. Zileuton, a new 5-lipoxygenase pathway inhibitor. ACI International 1996,8:134.
36. Nasser SM, Bell GS, Foster S, Spruce KE, MacMillan R, Williams AJ et al Effect of the 5-lipoxygenase inhibitor ZD-2138 on aspirin-induced asthma. Thorax 1994;49:749-56
37. Hedqvist P, Raud J, Palmertz U, Kumlin M, Dahlen SE. Eicosanoids as mediators and modulators of inflammation. Adv Prostaglandin Thromboxane Leukot Res 1991;21B:537-43
38. McMillan RM, Spruce KE, Crawley GC, Walker ER, Foster SJ. Preclinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase. Br J Pharmacol 1992; 107.1042-7.
39. Asano M, Inamura N, Nakahara K, Nagayoshi T, Isono T, Hamada K et al A 5-lipoxygenase inhibitor FR-110302, suppresses hyperresponsiveness and lung eosinophilia induced by Sepharex particles in rats. Agents Actions 1992;36:215-21.
40. Wegner CD, Gundel RH, Abraham WM The role of 5-lipoxygenase products in preclinical models of asthma. J Allergy Clin Immunol 1993;91:917-29
41. Howart PH, Harrison K, Lau L, Dube L, Cohn J. The influence of the 5-lipoxygenase inhibitor A-78773 on the nasal response to allergen in rhinitis J Allergy Clin Immunol 1994,93:297
42. Bell RL, Bouska JB, Malo PE, Lanni C, Harris RR, Otis ER et al. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors J Pharmacol Exp Ther 1995;272:724-31
43. Carter GW, Bell RL, Marsh K, Lanni C, Awni C, Bouska J et al Stereoselective metabolism of the 5-lipoxygenase inhibitor A-78773. An N Y Acad Sci 1994;744:262-73
44. Smith WG, Shaffer AF, Currie JL, Thompson JM, Kin S, Rao T et al Characterization of 5-lipoxygenase inhibitors in biochemical and functional in vivo assays. J Pharmacol Exp Ther 1995;275:1332-8.
45. Brooks CD, Stewart AO, Basha A, Bhatia P, Ratajczyk JD, Martin JG et al. (R)-(+)-N-[3-[5-[(4-fluorophenyl) methyl] -2-thienyl]-1-methyl-2-propynyl-hydroxyurea(ABT-761), a second generation 5-lipoxygenase inhibitor. J Med Chem 1995;38: 4768-75
46. Chauret N, Nicoll-Griffith D, Friesen R, Li C, Trimble L, Dube D et al. Microsomal metabolism of the 5-lipoxygenase inhibitors L-746530 and L-739010 to reactive immediates that covalenty bind to protein: the role of the 6,8-dioxabicyclo [3.2.1] octanyl moiety. Drugs Metab Dispos 1995;23:12:1325-34.
47. Hutchison JH, Riendeau D, Brideau C, Chan C, Falgueyret JP, Guay J et al. Thiopyrano [2,3,4-cd] indoles as 5-lipoxygenase inhibitors: syntesis, biological profile, and resolution of 2-[2-[1-(4-chorobenzyl)-4-methyl-6-[(5-phenylpyridin-2yl]A5-dihidro-1 H-thiopyrano [2,3,4-cd] indol-2-yl] ethoxy] butanoic acid. J Med Chem 1994;37:8:1153-64
48. Kusner EJ, Bucker CK, Dea DM, DeHaas CJ, Marks RL, Krell RD. The 5-lipoxygenase inhibitors ZD-2138 and ZM-230487 are potent and selective inhibitors of several antigen-induced guinea-pig pulmonary responses. Eur Pharmacol 1994;257: 3.285-92.